Poliartritis vertebro raquídeas: A propósito de las espondiloartropatías
Keywords:
enfermedades reumáticas, espondiloartropatías, dolor, inflamaciónAbstract
Introducción: Las espondiloartropatías pertenecen al grupo de las enfermedades reumáticas, de las cuáles el síntoma predominante es el dolor y la inflamación de las articulaciones, afectando en ocasiones a la columna vertebral
Objetivo: hacer una descripción general sobre diferentes tipos de espondiloartropatías, profundizando en aspectos tales como causas, consecuencias, diagnóstico y el tratamiento.
Desarrollo: Las espondiloartropatías se agrupan a través de ciertos factores genéticos predisponentes y características clínicas, pero muestran características clínicas distintas. Dentro de las más frecuentes se pueden destacar: la espondilitis anquilosante, la artritis reactiva y síndrome de Reiter, la artritis psoriásica, la espondiloartropatía asociada con la enfermedad inflamatoria intestinal y la espondiloartropatía indiferenciada.
Conclusiones: Los reumatólogos deben garantizar el manejo adecuado de esta enfermedad, garantizando el control de sus síntomas y el avance desmedido de la misma, logrando una adecuada combinación terapéutica de los fármacos biológicos y los sintéticos, además de la orientación y educación a los pacientes.
Downloads
References
Mallen CD, Helliwell T, Scott IC. How can primary care physicians enhance the early diagnosis of rheumatic diseases? Expert Rev Clin Immunol [Internet]. 2018 [citado 14 Ene 2024];14(3):171-3. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29338450/
Barbour KE, Helmick CG, Boring M, Brady TJ. Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2013-2015. MMWR Morb Mortal Wkly Rep [Internet]. 2017 [citado 14 Ene 2024];66(9):246-53. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28278145/
Proft F, Poddubnyy D. Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. Ther Adv Musculoskelet Dis [Internet]. 20188 [citado 14 Ene 2024];10(5-6):129-39. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29942364/
van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis [Internet]. 2017 [citado 14 Ene 2024];76(6):978-91. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28087505/
Sparks JA, Costenbader KH. Genetics, environment, and gene-environment interactions in the development of systemic rheumatic diseases. Rheum Dis Clin North Am [Internet]. 2014 [citado 14 Ene 2024];40(4):637-57. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25437282/
Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis [Internet]. 2011 [citado 14 Ene 2024];70(1):25-31. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21109520/
Zashin S. Explicación de la espondiloartropatía. Los seis tipos están relacionados, pero varían en sus síntomas específicos; 2021. [Internet] [citado 14 Ene 2024]. Disponible en: https://www-verywellhealth-com.translate. goog/spondyloarthropathy-explained-190443?
Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol [Internet]. 2016 [citado 14 Ene 2024];68(2):282-98. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26401991/
van Tubergen A. The changing clinical picture and epidemiology of spondyloarthritis. Nat Rev Rheumatol [Internet]. 2015 [citado 14 Ene 2024];11(2):110-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25385414/
Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis [Internet]. 2009 [citado 14 Ene 2024];68(6):777-83. Disponible en: https://pubmed.ncbi.nlm.nih.gov/19297344/
Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis [Internet]. 2011 [citado 14 Ene 2024];70(1):25-31. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21109520/
Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et at. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol [Internet]. 2019 [citado 14 Ene 2024];71:1599. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31436036/
Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol [Internet]. 2006 [citado 14 Ene 2024];33(9):1805-12. Disponible en: https://pubmed.ncbi.nlm.nih.gov/16960941/
Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, Regourd E, May M. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis [Internet]. 2008 [citado 14 Ene 2024];67(3):323-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17616556/
Poddubnyy D, Listing J, Sieper J. Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial. Arthritis Rheumatol [Internet]. 2016 [citado 14 Ene 2024];68(8):1899-903. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27015283/
Poddubnyy D, Sieper J. Treatment of Axial Spondyloarthritis: What Does the Future Hold? Curr Rheumatol Rep [Internet]. 2020 [citado 14 Ene 2024];22(9):47. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32691259/
American College of Rheumatology. Spondyloarthritis. Patient Fact Sheet; 2020. [Internet] [citado 14 Ene 2024]. Disponible en: https://www.rheumatology.org/Portals/0/Files/Spondyloarthritis-Fact-Sheet.pdf
Kataria R, Brent L. Spondyloarthropathies. American Academy of Family Physicians [Internet]. 2004 [citado 14 Ene 2024];69(12):2853-60. Disponible en: https://www.aafp.org/pubs/afp/issues/2004/0615/p2853.pdf
Chen HH, Chen TJ, Chen YM, Ying-Ming C, Chen DY. Gender differences in ankylosing spondylitis-associated cumulative healthcare utilization: a population-based cohort study. Clinics (Sao Paulo) [Internet]. 2011 [citado 14 Ene 2024];66(2):251-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21484042/
Van der Linden S, van der Heijde D. Ankylosing spondylitis. In: Ruddy S, Harris ED Jr, Sledge CB, eds. Kelley’s Textbook of rheumatology. 6th ed. Philadelphia: Saunders, 2001. p. 1039-54.
Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet [Internet]. 2017 [citado 14 Ene 2024];390(10089):73-84. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28110981/
Oddubnyy D, Sieper J. What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both? Rheumatology (Oxford) [Internet]. 2018 [citado 14 Ene 2024];57(7):1145-50. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29040753/
Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R, Chitkara D, Vastesaeger N; All INFAST Investigators. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis [Internet]. 2014 [citado 14 Ene 2024];73(1):101-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23696633/
Barkhuizen A, Steinfeld S, Robbins J, West C, Coombs J, Zwillich S. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol [Internet]. 2006[citado 14 Ene 2024];33(9):1805-12. Disponible en: https://pubmed.ncbi.nlm.nih.gov/16960941/
Amor B. Reiter's syndrome. Diagnosis and clinical features. Rheum Dis Clin North Am [Internet]. 1998 [citado 14 Ene 2024];24(4):677- 95. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9891706/
Yu DT, Peng TF. Reiter’ssyndrome. In: Ruddy S, Harris ED Jr, Sledge CB, eds. Kelley’sTextbookofrheumatology. 6th ed. Philadelphia: Saunders; 2001. p. 1055-70.
Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Möttönen T, Hakola M, Korpela M, Sanila M, Parviainen J, Uksila J, Vainionpää R, Toivanen A. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis [Internet]. 2000 [citado 14 Ene 2024];59(7):565-70. Disponible en: https://pubmed.ncbi.nlm.nih.gov/10873968/
Chanussot C, Arena R. Psoriasis. Estudiodescriptivo y comorbilidadesen 114 pacientes. Dermatología Cosmética, Médica y Quirúrgica [Internet]. 2015 [citado 14 Ene 2024];13(1):20-23. Dsiponible en: https://www.medigraphic.com/pdfs/cosmetica/dcm-2015/dcm151d.pdf
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med [Internet]. 2017 [citado 14 Ene 2024];376(10):957-70. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28273019/
Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis [Internet]. 2020 [citado 14 Ene 2024];79(6):700-12. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32434812/
De Keyser F, Elewaut D, De Vos M, De Vlam K, Cuvelier C, Mielants H, et al. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am [Internet]. 1998 [citado 14 Ene 2024];24(4):785-813. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9891711/
Downloads
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
